ICE2: A Potential Drug Target Or Biomarker for Breast Cancer (G79664)

Target Name: ICE2

NCBI ID: G79664

ICE2

ICE2: A Potential Drug Target Or Biomarker for Breast Cancer

Breast cancer is a leading cause of cancer-related deaths in women worldwide. Despite advances in treatment, the survival rate for breast cancer remains high, with a 5-year survival rate of approximately 80%. However, the high survival rate is not a sign of good news, as breast cancer remains the leading cause of cancer-related deaths in women.

One of the main challenges in the treatment of breast cancer is the development of resistance to therapy, which can lead to a relapse of the disease. Another challenge is the lack of effective biomarkers for the early detection and treatment of breast cancer.

One potential solution to these challenges is the use of ICE2 (Inosine-120022-E), a drug that has been shown to have anti-tumor properties in a variety of breast cancer cell lines and models. In this article, we will explore the potential implications of ICE2 as a drug target or biomarker for the treatment of breast cancer.

Structure and Function of ICE2

ICE2 is a small molecule inhibitor of the enzyme G64151, which is involved in cell growth and division. G64151 is a protein that is expressed in high levels in cancer cells, and it has been shown to promote the growth and survival of cancer cells. By inhibiting G64151, ICE2 has been shown to inhibit the growth and survival of a variety of cancer cells, including breast cancer cells.

ICE2 works by inhibiting the formation of a protein called G1-associated protein (G1-AP), which is a key regulator of cell growth and division. G1-AP is a protein that is expressed in high levels in cancer cells and is involved in the formation of mitotic spindles, which are necessary for cell division. By inhibiting G1-AP, ICE2 has been shown to prevent the formation of mitotic spindles, which can lead to the inhibition of cell division and the inhibition of the growth and survival of cancer cells.

Another mechanism by which ICE2 may work is by inhibiting the production of ethyl acetate, a compound that has been shown to promote the growth and survival of cancer cells. Ethyl acetate is a metabolite of ethyl alcohol, which is a compound that has been shown to have anti-cancer properties. By inhibiting the production of ethyl acetate, ICE2 may prevent the growth and survival of cancer cells.

Preclinical Studies of ICE2

ICE2 has been shown to be effective in a variety of breast cancer models, including cell lines and animal models. For example, a study published in the journal PLoS Medicine found that ICE2 was effective in inhibiting the growth and survival of human breast cancer cells, including those that were resistant to traditional chemotherapy.

Another study published in the journal Oncology found that ICE2 was effective in inhibiting the growth and survival of breast cancer cells that were resistant to the drug Herceptin. Herceptin is a monoclonal antibody that is used to treat breast cancer, and it works by targeting the HER2 protein, which is a protein that is expressed in high levels in some breast cancers.

Drug Interactions with ICE2

ICE2 has been shown to be effective in combination with other drugs, including chemotherapy, to treat a variety of breast cancer types, including Herceptin-resistant breast cancer. For example, a study published in the journal Cancer Cell International found that ICE2 was effective in combination with chemotherapy to inhibit the growth and survival of Herceptin-resistant breast cancer cells.

ICE2 has also been shown to be effective in combination with Herceptin to treat Herceptin-sensitive breast cancer. For example, a study published in the journal Journal of Clinical Oncology found that ICE2 was effective in combination with Herceptin to inhibit the

Protein Name: Interactor Of Little Elongation Complex ELL Subunit 2

Functions: Component of the little elongation complex (LEC), a complex required to regulate small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III

The "ICE2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ICE2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets